Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Algorae PharmaceuticalsASX:1AI EV-to-OCF is -31.93 as of Jul. 21, 2026. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Algorae Pharmaceuticals ranks better than 88.66% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Algorae Pharmaceuticals's Enterprise Value is A$22.45 Mil.
Algorae Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.70 Mil. Therefore, Algorae Pharmaceuticals's EV-to-OCF for today is -31.93.
The historical rank and industry rank for Algorae Pharmaceuticals's EV-to-OCF or its related term are showing as below:
ASX:1AI'
s EV-to-OCF Range Over the Past 10 Years
Min: -34.82 Med: -0.23 Max: 0.85
Current: -34.82
During the past 13 years, the highest EV-to-OCF of Algorae Pharmaceuticals was 0.85. The lowest was -34.82. And the median was -0.23.
ASX:1AI's EV-to-OCF is ranked better than 88.66% of 1411
companies
in the Biotechnology industry
Industry Median: -3.26
vs ASX:1AI: -34.82
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Algorae Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Algorae Pharmaceuticals's share price for today is A$0.012.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Algorae Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Algorae Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Algorae Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Algorae Pharmaceuticals's EV-to-OCF falls into.
Algorae Pharmaceuticals's current Enterprise Value is A$22.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Algorae Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Algorae Pharmaceuticals (ASX:1AI) has a EV-to-OCF of -31.93 as of Jul. 21, 2026. According to the industry distribution chart, Algorae Pharmaceuticals ranks #160 out of 1411 companies in the Biotechnology industry, placing it in the top 11.3%.
Is Algorae Pharmaceuticals' EV-to-OCF too high?
Algorae Pharmaceuticals' current EV-to-OCF is -31.93. Based on the distribution chart, Algorae Pharmaceuticals ranks #160 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Algorae Pharmaceuticals' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #160 out of 1411 companies for EV-to-OCF. This places Algorae Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Algorae Pharmaceuticals's current EV-to-OCF is -31.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current EV-to-OCF of -31.93. The current EV-to-OCF is -31.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current EV-to-OCF is -31.93 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:1AI has been successfully added to your 
